Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms – Claims Data Analysis: Immune Thrombocytopenic Purpura – Refreshed Dashboard 2021 (US)
Immune thrombocytopenia purpura (ITP) is an autoimmune form of acquired thrombocytopenia that leads to a decrease in platelet production and an increased risk of bleeding. Current therapies for ITP can be broadly divided into immunomodulators and thrombopoietin receptor agonists (TPO–RAs). Systemic glucocorticoids and TPO–RAs are the cornerstones of clinical management; however, biologics such as Roche’s Rituxan (rituximab, biosimilars) provide additional options for refractory patients. In 2018, two novel therapies for chronic ITP—Rigel Pharmaceuticals’ Tavalisse, an oral Syk inhibitor, and Dova Pharmaceuticals’ Doptelet (avatrombopag), a second-generation TPO–RA—launched in the United States. With the treatment landscape continuing to evolve, this report offers insights from real-world claims data into prescribing trends in ITP to help new players better understand current treatment practices in ITP that may help define the market niche for their emerging product.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed ITP patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed ITP patients?
- How have systemic steroids and TPO–RAs been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of ITP patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of ITP patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product Description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients. In addition, the dashboard features multiple data refreshes after report publication.
Archita Kukreja, M.B.A., M.S., Lead Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematologic Disorders. Archita has authored reports on hematological indications like beta thalassemia and sickle cell disease, infectious diseases, and several niche and rare indications. Prior to joining Clarivate, she was a Manager at Sanofi. She has worked on diverse custom and syndicated research project types in several therapeutic areas and has experience in sales- and epidemiology-based forecasting, demand forecasting, commercial opportunity assessments, and market intelligence. She holds double master’s degrees in business administration (M.B.A) and in science (M.S.) with specialization in Biotechnology from Amity University, Noida, India, and Jamia Millia Islamia University, Delhi, India, respectively.